JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion
JCR Pharmaceuticals Celebrates Rare Disease Day 2024
JCR’s Research Presentations at WORLDSymposium™ 2024 Showcase JR-141
JCR Pharmaceuticals to Present at the 20th Annual WORLDSymposium™ 2024
JCR Pharma and Takeda Announce Discontinuation of Gene Therapy Collaboration
U.S. FDA Grants Orphan Drug Designation to JR-441 for the Treatment of MPS IIIA
Modalis and JCR Pharmaceuticals enter into joint research agreement
JCR Pharma Announces First Patient Dosed in a Phase I/II Trial of JR-441
JCR Pharmaceuticals Announces 52-Week Interim Data from its Global Phase I/II Study of JR-171 in Individuals with Mucopolysaccharidosis Type I (MPS I)
AstraZeneca and its rare disease unit Alexion are doing a deal with JCR Pharmaceuticals, which will see them use JCR’s technology to try to develop a drug that can cross the blood-brain barrier for an undisclosed neurodegenerative disease.